---
layout: default
title: Activated Charcoal Anamirta Cocculus Seed Apis Mel
parent: 僅模型預測 (L5)
nav_order: 177
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Anamirta Cocculus Seed Apis Mel
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Preparation (Activated Charcoal / Nux Vomica / Tobacco Leaf et al.): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This submission covers a 10-component mixture — including activated charcoal, Nux vomica seed, Tobacco leaf, Silybum marianum, and several botanical/mineral ingredients — that carries no regulatory approvals in any reviewed market.
The TxGNN model generated **no predicted indications** for this entry, and critical data including mechanism of action and original approved use are unavailable.
A full repurposing evaluation **cannot be completed** until foundational data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No predictions or supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## About This Preparation

This candidate is not a single molecular entity but a **multi-ingredient mixture** composed of the following components:

| # | Ingredient | Category |
|---|-----------|----------|
| 1 | Activated Charcoal | Mineral / Adsorbent |
| 2 | Anamirta cocculus seed | Botanical (contains picrotoxin) |
| 3 | Apis mellifera | Animal-derived (honeybee) |
| 4 | Passiflora incarnata top | Botanical (passionflower) |
| 5 | Phosphoric acid | Mineral / Acid |
| 6 | Potassium phosphate, dibasic | Mineral / Salt |
| 7 | Semecarpus anacardium juice | Botanical (marking nut, toxic resin) |
| 8 | Silybum marianum seed | Botanical (milk thistle) |
| 9 | Strychnos nux-vomica seed | Botanical (contains strychnine) |
| 10 | Tobacco leaf | Botanical (contains nicotine) |

This combination profile is consistent with a **homeopathic or Ayurvedic compound preparation**, where ingredients such as Nux vomica, Cocculus, and Apis are classic homeopathic remedies used at high dilutions. However, because no DrugBank ID, INN, or approved indication was identified, this could not be confirmed, and no TxGNN node mapping was possible.

---

## Why No TxGNN Prediction Was Generated

TxGNN operates on the knowledge graph by mapping a drug to a single DrugBank node, then traversing disease relationships. This preparation has **no DrugBank ID**, which means:

1. None of the 10 components could be collectively mapped as a single drug entity.
2. Individual components may exist in DrugBank separately (e.g., Silybum marianum → silymarin; Tobacco leaf → nicotine), but multi-ingredient homeopathic mixtures are outside the current TxGNN knowledge graph scope.
3. Without a graph node, no disease-repurposing score can be computed.

---

## US Market Information

No regulatory authorizations were found. This preparation is **not marketed** under the queried name in the reviewed database.

---

## Safety Considerations

Several components in this mixture carry significant inherent toxicity concerns that warrant attention before any further evaluation:

- **Strychnos nux-vomica seed** contains strychnine — a potent convulsant with a narrow therapeutic window.
- **Anamirta cocculus seed** contains picrotoxin — a GABA antagonist with seizure-inducing potential.
- **Semecarpus anacardium juice** contains caustic bhilawanol resin — associated with skin burns and systemic toxicity.
- **Tobacco leaf** contains nicotine — cardiovascular and neurological risks at non-diluted concentrations.

If this is a homeopathic preparation with extreme dilutions (e.g., 30C), the above concerns may not apply in practice. However, **this cannot be confirmed from available data**.

Please refer to the product-specific package insert and relevant regulatory authority guidance for applicable safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This entry lacks a DrugBank ID, approved indication, mechanism of action, and TxGNN prediction output — the minimum data required to evaluate repurposing potential. The multi-component, likely homeopathic nature of this mixture places it outside the current TxGNN knowledge graph scope.

**To proceed, the following is needed:**

- **Clarify product identity**: Confirm whether this is a homeopathic preparation (with dilution levels), an Ayurvedic combination product, or a non-diluted botanical compound.
- **Identify authoritative monograph**: Locate any pharmacopoeia monograph (e.g., HPUS, Ayurvedic Pharmacopoeia of India) that defines the intended use.
- **DrugBank / individual component mapping**: If repurposing is desired for a specific active component (e.g., silymarin from Silybum marianum), resubmit that single ingredient as a separate candidate.
- **Safety documentation**: If this preparation is intended for clinical development, obtain full toxicity profiles for the non-diluted components, particularly Nux vomica and Cocculus.
- **Regulatory pathway clarification**: Determine which regulatory framework applies (homeopathic, botanical drug, traditional medicine) before initiating any repurposing pathway.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

